Your Navigation:PCAR > Abstract
Search pcar
Pharmaceutical Care and Research: 2019; 19(2):150-153
DOI: 10.5428/pcar20190219
One case analysis of clopidogrel resistance combined with ticagrelor allergy
1. CHANG Zhenzhen(a
Welcome to PCAR! You are the number 46 reader of this article!
Please cite this article as:
CHANG Zhenzhen,. One case analysis of clopidogrel resistance combined with ticagrelor allergy[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(2): 150-153.
1. Cardio-Cerebrovascular Diseases Professional Committee of China Gerontological Society,Cardio-Cerebrovascular Diseases Professional Committee of Chinese Rehabilitation Medicine Association. Chinese expert consensus on the treatment of stable coronary artery disease by oral antiplatelet drugs[J]. Chin J Cardiol,2016,44(2): 104-111. In Chinese.
2. Branch of Cardiovascular Diseases,Chinese Medical Association;Editorial Board of Chinese Journal of Cardiology. Chinese expert advice on clinical detection and treatment of antiplatelet therapy response diversity[J]. Chin J Cardiol,2014,42(12):986-991.In Chinese.
3. Mehta S R,Bainey K R,Cantor W J,et al.2018 Canadian Cardiovascular Society (CCS)/Canadian Association of Interventional Cardiology (CAIC) focused update of the guidelines for the use of antiplatelet therapy[J]. Can J Cardiol,2018,34(3):214-233.
4. HUI Gang,SONG Dandan,QI Chao,et al.Application of single gene polymorphism in the diagnosis of cardiovascular diseases[J].Chin J Lab Diagn,2018,22(3):543-546.In Chinese.
5. Thrombosis Prevention and Therapy Professional Committee of Branch of Cardiovascular Physicians,Chinese Medical Doctor Association; Interventional Group of Branch of Cardiovascular Diseases,Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. Chinese expert consensus on clinical application of ticagrelor[J]. Chin J Cardiol,2016,44(2):112-120. In Chinese.
6. Wallentin L,James S,Storey R F,et al.Effect of CYP2C19 and ABCBl single nucleotide polymorphisms on the outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes:a genetic substudy of the PLATO trial [J].Lancet,2010,376:1320-1328.
7. CHEN Yundai,DONG Wei,WAN Zheng,et al.Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome:a pharmacodynamic analysis[J].Int J Cardiol,2015,201:545-546.
8. LI Zhihua,ZHANG Yachen,XIE Yuquan,et al.Clinical efficacy and safety of ticagrelor in acute coronary syndrome patients receiving percutaneous coronary intervention [J].Chin J Intervent Cardiol,2015,23(8):446-450.In Chinese with English abstract.
9. ZHANG Jianhong,ZHU Liqin,TIAN Danli,et al.Adverse drug reactions induced by ticagrelor:an analysis of domestic and foreign literature[J]. Chin J New Drugs,2017,26 (11):1335-1338. In Chinese with English abstract.
10. Ikram S,Veerappan Kandasamy V.Ticagrelor-induced sweet syndrome: an unusual dermatologic complication after percutaneous coronary intervention [J]. Cardiovasc Interv Ther,2017,32(3):244-246.
11. TU Qiang,CAO Zheng. Progress in the pharmacological effect and clinical application of cilostazol[J]. Chin J Arterioscler,2017,25(6):644-648. In Chinese with English abstract.
12. HAN Yaling,LI Yi,WANG Shouli,et al.Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes:a randomized,controlled study[J].Am Heart J,2009,157(4):733-739.
13. ZHANG Bin,CHU Zhenliang,JIANG Liqin,et al. Effect of cilostazol on ACS patients carrying CYP2C19*2 gene associated with high on-treatment platelet reactivity[J]. Prevent Treat Cardio-Cereb-Vasc Dis,2017,17(5):344-346,363. In Chinese with English abstract.
14. Johnson D A,Katz P O,Armstrong D,et al.The safety of appropriate use of over-the-counter proton pump inhibitors: an evidence-based review and Delphi consensus[J].Drugs,2017,77(5):547-561.
15. Evaluation Working Group of Statin Safety. Expert consensus on statin safety evaluation[J]. Chin J Cardiol,2014,42(11):890-894.In Chinese.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330